Vistagen Therapeutics, Inc. (VTGN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Shawn K. Singh J.D. | CEO & Director | 600k | -- | 1963 |
| Mr. Reid G. Adler Esq., J.D. | Chief Corporate Development Officer & General Counsel | 371.88k | -- | 1955 |
| Ms. Cynthia Lynn Anderson CPA | Chief Financial Officer | -- | -- | 1969 |
| Mr. Mark Adrian McPartland | Senior Vice President of Investor Relations | 300k | -- | 1966 |
| Ms. Trisha Fitzmaurice | Senior Vice President of Human Resources | -- | -- | -- |
| Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Development Operations | -- | -- | -- |
| Dr. Mark J. Ginski Ph.D. | Senior VP and Head of Chemistry, Manufacturing & Controls | -- | -- | 1972 |
| Mr. Mark Flather | Senior Vice President of Corporate Strategy & Capital Markets | -- | -- | -- |
| Dr. Erik Berglund M.D., Ph.D. | Senior VP of Global Regulatory Affairs & Pharmacovigilance | -- | -- | -- |
| Dr. Louis Monti | Senior Vice President of Translational Neuroscience | -- | -- | -- |
Vistagen Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 37
Description
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 16, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 05, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 27, 2024CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing
- Feb 13, 2024S-3: Offering RegistrationsSee Full Filing